Figure 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A

Figure 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A

<p>CD4<sup>+</sup> T cells induced by cobolimab (<b>A</b>) and combined cobolimab and dostarlimab (<b>B</b>). Percentage of single cells with transcript expression of TIM-3, PD-1, and their ligands in baseline and anti–PD-1–treated samples across key immune...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας: Diwakar Davar (15023480) (author)
Άλλοι συγγραφείς: Zeynep Eroglu (19276519) (author), Casilda Llácer Pérez (22053013) (author), Brian Di Pace (22053016) (author), Tianli Wang (22053019) (author), Niranjan Yanamandra (22053022) (author), Srimoyee Ghosh (22053025) (author), Kathrin Jansen (22053028) (author), Arindam Dhar (15016280) (author), Theo Borgovan (22053031) (author), Angela Waszak (22053034) (author), Antoni Ribas (14837278) (author)
Έκδοση: 2025
Θέματα:
Cancer
Cancer Biology
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Phase I clinical trials
Immunotherapy
Antibody immunotherapy
Checkpoint blockade
Oncogenes & Tumor Suppressors
PD-1
Skin Cancers
Melanoma
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια